Search results for "Transplant"

showing 10 items of 2137 documents

2017

Allogeneic hematopoietic stem cell transplantation is the only curative treatment option for several hematological malignancies and immune deficiency syndromes. Nevertheless, the development of a graft-versus-host disease (GvHD) after transplantation is a high risk and a severe complication with high morbidity and mortality causing therapeutic challenges. Current pharmacological therapies of GvHD lead to generalized immunosuppression followed by severe adverse side effects including infections and relapse of leukemia. Several novel cell-based immunomodulatory strategies for treatment or prevention of GvHD have been developed. Herein, thymus-derived regulatory T cells (tTreg), essential for …

0301 basic medicinebusiness.industryRegulatory T cellmedicine.medical_treatmentImmunologyImmunosuppressionHematopoietic stem cell transplantationmedicine.diseaseCell therapyTransplantation03 medical and health sciencesLeukemia030104 developmental biologymedicine.anatomical_structureGraft-versus-host diseaseImmunologyHumanized mousemedicineImmunology and AllergybusinessFrontiers in Immunology
researchProduct

Ophthalmological Findings in Mucopolysaccharidoses

2019

The mucopolysaccharidoses (MPS) are a heterogenous group of lysosomal storage disorders caused by the accumulation of glycosaminoglycans (GAGs). The accrual of these compounds results in phenotypically varied syndromes that produce multi-organ impairment with widespread systemic effects. The low incidence of MPS (approximately 1/25,000 live births) in conjunction with the high childhood mortality rate had limited the availability of research into certain clinical features, especially ocular manifestations. As the recent successes of hematopoietic stem cell transplantation (HSCT) and enzyme replacement therapy (ERT) have greatly increased life expectancy in these patients, they have served a…

0301 basic medicinecongenital hereditary and neonatal diseases and abnormalitiesPediatricsmedicine.medical_specialtygenetic structuresmedicine.medical_treatmentMucopolysaccharidosislcsh:MedicineGlaucomaReviewHematopoietic stem cell transplantation03 medical and health sciences0302 clinical medicineQuality of lifeCorneal cloudingmedicinebusiness.industryMortality rateIncidence (epidemiology)lcsh:Rnutritional and metabolic diseasesmucopolysaccharidosisGeneral MedicineEnzyme replacement therapymedicine.diseaseocular manifestationseye diseasesophthalmology030104 developmental biologycorneal clouding030221 ophthalmology & optometrylysosomal storage disordersense organsbusinessJournal of Clinical Medicine
researchProduct

Cytomegalovirus infection management in solid organ transplant recipients across European centers in the time of molecular diagnostics: An ESGICH sur…

2017

Background Scant information is available about how transplant centers are managing their use of quantitative molecular testing (QNAT) assays for active cytomegalovirus (CMV) infection monitoring in solid organ transplant (SOT) recipients. The current study was aimed at gathering information on current practices in the management of CMV infection across European centers in the era of molecular testing assays. Methods A questionnaire-based cross-sectional survey study was conducted by the European Study Group of Infections in Immunocompromised Hosts (ESGICH) of the Society of Clinical Microbiology and Infectious Diseases (ESCMID). The invitation and a weekly reminder with a personal link to …

0301 basic medicinecytomegalovirus; solid organ transplantation; survey.cytomegalovirus ; solid organ transplantation ; surveyCross-sectional studyCytomegalovirusTransplantsPractice Patterns030230 surgeryOrgan transplantationlaw.invention0302 clinical medicinePostoperative Complicationslaw03.02. Klinikai orvostanViralPractice Patterns Physicians'solid organ transplantationPolymerase chain reactionViral LoadEuropeInfectious DiseasesCytomegalovirus InfectionsPractice Guidelines as Topiccytomegalovirus; solid organ transplantation; survey; Antibiotic Prophylaxis; Antiviral Agents; Cross-Sectional Studies; Cytomegalovirus; Cytomegalovirus Infections; DNA Viral; Europe; Guideline Adherence; Health Care Surveys; Humans; Immunocompromised Host; Immunosuppression; Organ Transplantation; Postoperative Complications; Practice Guidelines as Topic; Practice Patterns Physicians'; Real-Time Polymerase Chain Reaction; Transplant Recipients; Transplants; Viral LoadGuideline Adherencecytomegalovirus; solid organ transplantation; survey; Antibiotic Prophylaxis; Antiviral Agents; Cross-Sectional Studies; Cytomegalovirus; Cytomegalovirus Infections; DNA Viral; Europe; Guideline Adherence; Health Care Surveys; Humans; Immunocompromised Host; Immunosuppression; Organ Transplantation; Postoperative Complications; Practice Guidelines as Topic; Practice Patterns Physicians'; Real-Time Polymerase Chain Reaction; Transplant Recipients; Transplants; Viral Load; Transplantation; Infectious Diseasesmedicine.medical_specialty030106 microbiologyCongenital cytomegalovirus infectionReal-Time Polymerase Chain ReactionAntiviral Agents03 medical and health sciencesImmunocompromised HostmedicineHumanssurveyIntensive care medicineImmunosuppression TherapyTransplantationPhysicians'business.industryDNAOrgan TransplantationAntibiotic Prophylaxismedicine.diseaseMolecular diagnosticsTransplant RecipientsCytomegalovirus infectionTransplantationcytomegalovirus; solid organ transplantation; survey; Transplantation; Infectious DiseasesCross-Sectional StudiesCytomegalovirus; Solid organ transplantation; Survey; Transplantation; Infectious DiseasesHealth Care SurveysDNA ViralImmunologySolid organ transplantationbusinessImmunosuppression
researchProduct

2016

Successful reconstitution of cytomegalovirus (CMV)-specific CD8+ T cells by hematopoietic cell transplantation (HCT) gives a favorable prognosis for the control of CMV reactivation and prevention of CMV disease after hematoablative therapy of hematopoietic malignancies. In the transient immunocompromised state after HCT, pre-emptive cytoimmunotherapy with viral epitope-specific effector or memory CD8+ T cells is a promising option to speed up antiviral control. Despite high-coding capacity of CMVs and a broad CD8+ T-cell response on the population level, which reflects polymorphism in major histocompatibility complex class-I (MHC-I) glycoproteins, the response in terms of quantity of CD8+ T…

0301 basic medicineeducation.field_of_studyAdoptive cell transferbiologyImmunologyPopulationImmunodominanceMajor histocompatibility complexVirologyEpitopeTransplantation03 medical and health sciences030104 developmental biologyImmunologybiology.proteinImmunology and AllergyCytotoxic T celleducationCD8Frontiers in Immunology
researchProduct

Transplantation of ACE2- Mesenchymal Stem Cells Improves the Outcome of Patients with COVID-19 Pneumonia

2020

A coronavirus (HCoV-19) has caused the novel coronavirus disease (COVID-19) outbreak in Wuhan, China. Preventing and reversing the cytokine storm may be the key to save the patients with severe COVID-19 pneumonia. Mesenchymal stem cells (MSCs) have been shown to possess a comprehensive powerful immunomodulatory function. This study aims to investigate whether MSC transplantation improves the outcome of 7 enrolled patients with COVID-19 pneumonia in Beijing YouAn Hospital, China, from Jan 23, 2020 to Feb 16, 2020. The clinical outcomes, as well as changes of inflammatory and immune function levels and adverse effects of 7 enrolled patients were assessed for 14 days after MSC injection. MSCs …

0301 basic medicinefunction recoverymedicine.medical_specialtyPopulationimmunomodulationGastroenterologyPathology and Forensic MedicineImmunomodulation03 medical and health sciences0302 clinical medicineImmune systemInternal medicinemedicinecell transplantationAdverse effecteducationSettore MED/04 - Patologia Generalemesenchymal stem cellseducation.field_of_studybusiness.industryMesenchymal stem cellCOVID-19Cell Biologymedicine.diseaseFunction recoveryACE2 negativeTransplantationPneumonia030104 developmental biologyMesenchymal stem cellsNeurology (clinical)Cell transplantationGeriatrics and GerontologybusinessCytokine storm030217 neurology & neurosurgeryCD8Aging and disease
researchProduct

Mitochondrial targeting as a novel therapy for stroke

2018

Stroke is a main cause of mortality and morbidity worldwide. Despite the increasing development of innovative treatments for stroke, most are unsuccessful in clinical trials. In recent years, an encouraging strategy for stroke therapy has been identified in stem cells transplantation. In particular, grafting cells and their secretion products are leading with functional recovery in stroke patients by promoting the growth and function of the neurovascular unit – a communication framework between neurons, their supply microvessels along with glial cells – underlying stroke pathology and recovery. Mitochondrial dysfunction has been recently recognized as a hallmark in ischemia/reperfusion neur…

0301 basic medicinelcsh:Diseases of the circulatory (Cardiovascular) systemAginglcsh:Medical technologyimpaired mitochondriavasculatureBioenergeticmedicine.medical_treatmentClinical Trials and Supportive ActivitiesIschemiaregenerative medicineReview ArticleBioenergeticsMitochondrionblood–brain barrierBioinformaticsstem cell therapycerebral ischemiaCell therapy03 medical and health sciences0302 clinical medicineClinical Researchmedicineneurovascular unitStrokeTransplantationbusiness.industryNeurosciencesGeneral MedicineStem-cell therapyblood-brain barrierStem Cell Researchmedicine.diseaseendothelial cellsBrain DisordersReview articleStrokeTransplantationtransfer of healthy mitochondria030104 developmental biologylcsh:R855-855.5lcsh:RC666-701endothelial cellStem cellbusiness030217 neurology & neurosurgeryBrain Circulation
researchProduct

Vγ9Vδ2 T Cells in the Bone Marrow of Myeloma Patients: A Paradigm of Microenvironment-Induced Immune Suppression

2018

Vγ9Vδ2 T cells are non-conventional T cells with a natural inclination to recognize and kill cancer cells. Malignant B cells, including myeloma cells, are privileged targets of Vγ9Vδ2 T cells in vitro. However, this inclination is often lost in vivo due to multiple mechanisms mediated by tumor cells and local microenvironment. Multiple myeloma (MM) is a paradigm disease in which antitumor immunity is selectively impaired at the tumor site. By interrogating the immune reactivity of bone marrow (BM) Vγ9Vδ2 T cells to phosphoantigens, we have revealed a very early and long-lasting impairment of Vγ9Vδ2 T-cell immune functions which is already detectable in monoclonal gammopathy of undetermined …

0301 basic medicinelcsh:Immunologic diseases. AllergyStromal cellbone marrowMini ReviewImmunologyVγ9Vδ2 T cells immune checkpoints multiple myeloma immune suppression bone marrow03 medical and health sciences0302 clinical medicineImmune systemAutologous stem-cell transplantationmedicineImmunology and AllergyMultiple myelomabusiness.industryimmune checkpointsmedicine.diseaseVγ9Vδ2 T cellsIn vitromultiple myeloma030104 developmental biologymedicine.anatomical_structure030220 oncology & carcinogenesisCancer cellCancer researchBone marrowimmune suppressionbusinesslcsh:RC581-607Monoclonal gammopathy of undetermined significanceFrontiers in Immunology
researchProduct

Interleukin-22 in Graft-versus-Host Disease after Allogeneic Stem Cell Transplantation

2016

International audience; Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a potential curative treatment for hematologic malignancies and non-malignant diseases. Because of the lower toxicity of reduced intensity conditioning, the number of transplants is in constant increase. However, allo-HSCT is still limited by complications, such as graft-versus-host disease (GVHD), which is associated with important morbidity and mortality. Acute GVHD is an exacerbated inflammatory response that leads to the destruction of healthy host tissues by donor immune cells. Recently, the contribution of innate immunity in GVHD triggering has been investigated by several groups and resulted in …

0301 basic medicinelcsh:Immunologic diseases. Allergy[SDV.IMM] Life Sciences [q-bio]/Immunologyalloreactivitymedicine.medical_treatmentImmunologyInflammationchemical and pharmacologic phenomenaHematopoietic stem cell transplantationReviewBiologyInterleukin 2203 medical and health sciencesgraft-versus-host-disease0302 clinical medicineImmune systemimmune system diseasesallogeneic stem cell transplantationmedicinegraft-versus-host diseaseImmunology and AllergyInflammationInnate immune systeminterleukin-22medicine.disease3. Good healthTransplantation030104 developmental biologyGraft-versus-host diseasesurgical procedures operativeImmunology[SDV.IMM]Life Sciences [q-bio]/Immunologymedicine.symptomStem celllcsh:RC581-607030215 immunology
researchProduct

In Vivo Articular Cartilage Regeneration Using Human Dental Pulp Stem Cells Cultured in an Alginate Scaffold: A Preliminary Study

2017

Osteoarthritis is an inflammatory disease in which all joint-related elements, articular cartilage in particular, are affected. The poor regeneration capacity of this tissue together with the lack of pharmacological treatment has led to the development of regenerative medicine methodologies including microfracture and autologous chondrocyte implantation (ACI). The effectiveness of ACI has been shown in vitro and in vivo, but the use of other cell types, including bone marrow and adipose-derived mesenchymal stem cells, is necessary because of the poor proliferation rate of isolated articular chondrocytes. In this investigation, we assessed the chondrogenic ability of human dental pulp stem c…

0301 basic medicinelcsh:Internal medicineArticle SubjectChemistryCartilageRegeneration (biology)0206 medical engineeringMesenchymal stem cell02 engineering and technologyCell BiologyAnatomyChondrogenesis020601 biomedical engineeringCell biology03 medical and health sciences030104 developmental biologymedicine.anatomical_structureDental pulp stem cellsmedicinelcsh:RC31-1245Autologous chondrocyte implantationMolecular BiologyAggrecanStem cell transplantation for articular cartilage repairResearch ArticleStem Cells International
researchProduct

Treatment of multiple myeloma-related bone disease

2021

In this Policy Review, the Bone Working Group of the International Myeloma Working Group updates its clinical practice recommendations for the management of multiple myeloma-related bone disease. After assessing the available literature and grading recommendations using the Grading of Recommendations, Assessment, Development, and Evaluations (GRADE) method, experts from the working group recommend zoledronic acid as the preferred bone-targeted agent for patients with newly diagnosed multiple myeloma, with or without multiple myeloma-related bone disease. Once patients achieve a very good partial response or better, after receiving monthly zoledronic acid for at least 12 months, the treating…

0301 basic medicinemedicine.medical_specialtyBone Density Conservation AgentBone disease03 medical and health sciences0302 clinical medicineSpinal cord compressionmedicineHumansMultiple myelomaBone Density Conservation Agentsbusiness.industrymedicine.diseaseSurgeryDiscontinuationTransplantationBone Density Conservation Agents030104 developmental biologyZoledronic acidDenosumabOncology030220 oncology & carcinogenesisPractice Guidelines as TopicBone DiseasesbusinessBone DiseaseMultiple Myelomamedicine.drugHumanThe Lancet Oncology
researchProduct